Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response

International Journal of Cancer

Volumn 99, Issue 4, 2002, Pages 573-578

  Yajima, Toshiki ^a,b   Nishimura, Hitoshi ^a   Wajjwalku, Worawidh ^c   Harada, Mamoru ^d   Kuwano, Hiroyuki ^b   Yoshikai, Yasunobu ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c KASETSART UNIVERSITY   (Thailand)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CTL; IL 15; NK cells; Transgenic mice; Tumor immunity

Indexed keywords

CD8 ANTIGEN; GENE PRODUCT; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE OVEREXPRESSION; GENE THERAPY; MELANOMA; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENES, MHC CLASS I; IMMUNOGLOBULIN G; INTERLEUKIN-15; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; SPLEEN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036605090     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10395     Document Type: Article

References (40)

1. The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells
2. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor
3. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation
4. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro
5. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host defense to intracellular pathogens
6. The role of interleukin 15 in mounting an immune response against microbial infections
7. Fatal leukemia in Interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8(+) T cells
8. + T cells in vivo by IL-15
9. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
10. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
11. Differential roles of Interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in vivo
12. Memory phenotype CD8(+) T cells in IL-15 transgenic mice are involved in early protection against a primary infection with Listeria monocytogenes
13. + T cell-mediated immunity against Toxoplasma gondii infection in mice
14. + T cell-mediated immunity in mice infected with vaccine strain of Toxoplasma gondii
15. Overexpression of Interleukin-15 in vivo enhances Tcl response which inhibits allergic inflammation in a murine model of asthma
16. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
17. Dissimilar anti-tumor reactions induced by tumour cells engineered with the interleukin-2 or inteleukin-15 gene in nude mice
18. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response
19. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations
20. Synergistic effect of IL-15 and IL-12 on anti-tumor activity in a murine malignant pleurisy model
21. Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency
22. - cells in metastatic processes
23. In vitro priming of cytotoxic T lymphocyters against poorly immunogenic epitopes by engineered antigen-presenting cells
24. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B 16 melanoma
25. Characterization of B16 melanomaspecific cytotoxic T lymphocytes
26. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
27. NK cell receptors
28. Regulation of the natural killer cell receptor repertoire
29. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor γ chain
30. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1
31. The effect of transfected MHC class I genes on sensitivity to natural killer cells
32. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
33. + tumor-infiltrating lymphocytes
34. Two types of murine helper T cell clone: I definition according to profiles of lymphokine activities and secreted proteins
35. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
36. + T-cell subsets in vivo
37. + T cells
38. + alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis
39. + T cells in IL-12-induced immune responses in vivo
40. + T cells on experimental haematogenous tumour metastasis in the liver and lungs of mice